🇺🇸 SECGSK plcCodex · 实盘不做把握 9/10不做原因:无增量信息
北京时间·🕒 发布 00:26:23·⟳ 抓取 00:26:46 +23s·⚡ 决策 09-02 00:29:40 +2m54s·56.1 天前
GSK披露截至2026年8月31日总投票权，属例行股本通知
事件为法定例行总投票权披露，仅提供权益通知分母，不构成基本面、资本回报或控制权变化催化。
📄 原文GSK plc↗ 原文
----- a9126s.htm ----- 6-K 1 a9126s.htm TOTAL VOTING RIGHTS a9126s UNITED STATES SECURITIES AND EXCHANGE COMMISSION Was…
不做 GSK plc（GSK.US）
例行总投票权披露不改变GSK plc（GSK.US）的基本面、股东回报或控制权预期，无交易edge。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
原始6-K显示GSK按FCA披露截至2026年8月31日的总投票权和库存股数量，该信息用于股东持股比例通知计算；公告没有新增经营、财务、监管、管线或资本配置事实，因此无明确方向和短线正期望。
🔎 新鲜度:最早出现 2026-09-01 · 扩散 low · price-in 风险 low ↗
主要风险
- 若同日另有独立财报、管线或资本配置公告，需要作为新事件另行评估；本6-K本身不提供交易边界。
先例如何影响了这次决策
对本次决策的影响:确认不做，不设置入场、止盈或止损。
方向:例行总投票权披露通常不提供方向性交易信号；本次无需用价格先例校准。
涨幅量级:无基本面增量，未建立可测幅度。
形态:不适用。
原文全文
展开原文 · 2,135 字
----- a9126s.htm -----
6-K
1
a9126s.htm
TOTAL VOTING RIGHTS
a9126s
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of September 2026
Commission
File Number 001-15170
GSK plc
(Translation
of registrant's name into English)
79 New Oxford Street, London, WC1A 1DG
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
Issued: 1 September 2026, London UK
Total Voting Rights
In conformity with the Financial Conduct Authority's
Disclosure Guidance and Transparency Rule 5.6.1R, GSK plc (the
'Company') hereby notifies the market of the
following:
The Company's issued share capital as at 31 August 2026
consisted of 4,316,302,379 shares of 31 ¼ pence each
('Ordinary Shares'), of which 270,881,064 Ordinary Shares
were held in Treasury.
Therefore, the total number of voting rights in the Company
is 4,045,421,315. This figure may be used by shareholders
as the denominator for the calculations by which they will
determine if they are required to notify their interest in, or a
change to their interest in, the Company under the Financial
Conduct Authority's Disclosure Guidance and Transparency
Rules.
Notifications may be sent to
company.secretary@gsk.com
.
V A Whyte
Company Secretary
1 September 2026
About GSK
GSK is a global biopharma company with a purpose to unite science,
technology, and talent to get ahead of disease together. Find out
more at
www.gsk.com
.
Registered in England & Wales:
No.
3888792
Registered Office:
79
New Oxford Street
London
WC1A
1DG
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
GSK plc
(Registrant)
Date: September
01, 2026
By:/s/ VICTORIA
WHYTE
--------------------------
Victoria Whyte
Authorised
Signatory for and on
behalf
of GSK plc
6-K
1
a9126s.htm
TOTAL VOTING RIGHTS
a9126s
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of September 2026
Commission
File Number 001-15170
GSK plc
(Translation
of registrant's name into English)
79 New Oxford Street, London, WC1A 1DG
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
Issued: 1 September 2026, London UK
Total Voting Rights
In conformity with the Financial Conduct Authority's
Disclosure Guidance and Transparency Rule 5.6.1R, GSK plc (the
'Company') hereby notifies the market of the
following:
The Company's issued share capital as at 31 August 2026
consisted of 4,316,302,379 shares of 31 ¼ pence each
('Ordinary Shares'), of which 270,881,064 Ordinary Shares
were held in Treasury.
Therefore, the total number of voting rights in the Company
is 4,045,421,315. This figure may be used by shareholders
as the denominator for the calculations by which they will
determine if they are required to notify their interest in, or a
change to their interest in, the Company under the Financial
Conduct Authority's Disclosure Guidance and Transparency
Rules.
Notifications may be sent to
company.secretary@gsk.com
.
V A Whyte
Company Secretary
1 September 2026
About GSK
GSK is a global biopharma company with a purpose to unite science,
technology, and talent to get ahead of disease together. Find out
more at
www.gsk.com
.
Registered in England & Wales:
No.
3888792
Registered Office:
79
New Oxford Street
London
WC1A
1DG
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
GSK plc
(Registrant)
Date: September
01, 2026
By:/s/ VICTORIA
WHYTE
--------------------------
Victoria Whyte
Authorised
Signatory for and on
behalf
of GSK plc
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。